Senior IT Support Engineer, LabGenius

Historically, the discovery of protein therapeutics has been a labour-intensive, human-driven process, with scientists manually designing and executing experiments. This traditional approach is limited by our cognitive abilities to fully understand the complexity of biological systems. LabGenius is breaking these barriers with EVA, a smart robotic platform that not only designs and conducts experiments but also learns from them This continuous learning allows EVA to refine its understanding of genetic design rules, growing smarter with each experiment.

Currently, LabGenius is deploying EVA to develop novel antibody fragments for therapeutic areas, including solid tumours, where they offer significant advantages over traditional antibody formats. EVA's ability to engineer high-value drug properties - such as efficacy, potency, selectivity, and manufacturability - addresses challenges that have long hindered the field. This is an exciting development for the team, and they are now exploring how these principles can be applied more broadly to tackle human diseases.